Sameer Quazi

Mr. Sameer Quazi

University of Manchester, Manchester, UK
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2021 in Discover Nano
Verified
Journal Article
Open access
PDF file
SGShreelaxmi Gavas
Shreelaxmi Gavas
SQSameer Quazi
Sameer Quazi
Tomasz M. KarpinskiTomasz M. Karpinski
Tomasz M. Karpinski
Cancer is one of the leading causes of death and morbidity with a complex pathophysiology. Traditional cancer therapies include chemotherapy, radiation therapy, targeted therapy, and immunotherapy. However, limitations such as lack of specificity, cytotoxicity, and multi-drug resistance pose a substantial challenge for favorable cancer treatment. The advent of nanotechnology has revolutionized the arena of cancer diagnosis and treatment. Nanoparticles (1–100 nm) can be used to treat cancer due to their specific advantages such as biocompatibility, reduced toxicity, more excellent stability, enhanced permeability and retention effect, and precise targeting. Nanoparticles are classified into several main categories. The nanoparticle drug delivery system is particular and utilizes tumor and tumor environment characteristics. Nanoparticles not only solve the limitations of conventional cancer treatment but also overcome multidrug resistance. Additionally, as new multidrug resistance mechanisms are unraveled and studied, nanoparticles are being investigated more vigorously. Various therapeutic implications of nanoformulations have created brand new perspectives for cancer treatment. However, most of the research is limited to in vivo and in vitro studies, and the number of approved nanodrugs has not much amplified over the years. This review discusses numerous types of nanoparticles, targeting mechanisms, and approved nanotherapeutics for oncological implications in cancer treatment. Further, we also summarize the current perspective, advantages, and challenges in clinical translation.


29 September 2022 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
MMMaryam Moghtaderi
Maryam Moghtaderi
KSKamand Sedaghatnia
Kamand Sedaghatnia
MBMahsa Bourbour
Mahsa Bourbour
MFMahdi Fatemizadeh
Mahdi Fatemizadeh
ZSZahra SALEHIMOGHADAM
Zahra SALEHIMOGHADAM
BFBahareh Farasati Far
Bahareh Farasati Far

16 April 2022 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
SQSameer Quazi
Sameer Quazi

24 August 2023 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
SQSameer Quazi
Sameer Quazi
The deadliest disease in the world, cancer, kills many people every year. The early detection is the only hope for the survival of malignant cancer patients. As a result, in the preliminary stages of, the diagnosis of cancer biomarkers at the cellular level is critical for improving cancer patient survival rates. For decades, scientists have focused their efforts on the invention of biosensors. Biosensors, in addition to being employed in other practical scenarios, can essentially function as cost effective and highly efficient devices for this purpose. Traditional cancer screening procedures are expensive, time-consuming, and inconvenient for repeat screenings. Biomarker-based cancer diagnosis, on the other hand, is rising as one of the most potential tools for early detection, disease progression monitoring, and eventual cancer treatment. As Biosensor is an analytical device, it allows the selected analyte to bind to the biomolecules being studied (for example RNA, DNA, tissue, proteins, and cells). They can be divided based on the kind of biorecognition or transducer elements on the sensor. Most biosensor analyses necessitate the analyte being labeled with a specific marker. In this review article, the application of distinct variants of biosensors against cancer has been described.

6 February 2023 in Biology
Verified
Journal Article
Open access
PDF file
BSBELAY ZELEKE SIBUH
BELAY ZELEKE SIBUH
SQSameer Quazi
Sameer Quazi
HPHrithika Panday
Hrithika Panday
RPRitika Parashar
Ritika Parashar
Niraj Kumar JhaNiraj Kumar Jha
Niraj Kumar Jha
AJAbhimanyu Kumar Jha
Abhimanyu Kumar Jha
Each cell in a multicellular organism has its own phenotype despite sharing the same genome. Epigenetics is a somatic, heritable pattern of gene expression or cellular phenotype mediated by structural changes in chromatin that occur without altering the DNA sequence. Epigenetic modification is an important factor in determining the level and timing of gene expression in response to endogenous and exogenous stimuli. There is also growing evidence concerning the interaction between epigenetics and metabolism. Accordingly, several enzymes that consume vital metabolites as substrates or cofactors are used during the catalysis of epigenetic modification. Therefore, altered metabolism might lead to diseases and pathogenesis, including endocrine disorders and cancer. In addition, it has been demonstrated that epigenetic modification influences the endocrine system and immune response-related pathways. In this regard, epigenetic modification may impact the levels of hormones that are important in regulating growth, development, reproduction, energy balance, and metabolism. Altering the function of the endocrine system has negative health consequences. Furthermore, endocrine disruptors (EDC) have a significant impact on the endocrine system, causing the abnormal functioning of hormones and their receptors, resulting in various diseases and disorders. Overall, this review focuses on the impact of epigenetics on the endocrine system and its interaction with metabolism.